CN119421710A - 偏头痛的预防治疗 - Google Patents

偏头痛的预防治疗 Download PDF

Info

Publication number
CN119421710A
CN119421710A CN202380026078.8A CN202380026078A CN119421710A CN 119421710 A CN119421710 A CN 119421710A CN 202380026078 A CN202380026078 A CN 202380026078A CN 119421710 A CN119421710 A CN 119421710A
Authority
CN
China
Prior art keywords
treatment
migraine
baseline
days
achieves
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380026078.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·特鲁格曼
M·芬尼根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elastagen Pty Ltd
Original Assignee
Elastagen Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elastagen Pty Ltd filed Critical Elastagen Pty Ltd
Publication of CN119421710A publication Critical patent/CN119421710A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202380026078.8A 2022-03-09 2023-03-09 偏头痛的预防治疗 Pending CN119421710A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263269105P 2022-03-09 2022-03-09
US63/269105 2022-03-09
US202263347265P 2022-05-31 2022-05-31
US63/347265 2022-05-31
US202263404352P 2022-09-07 2022-09-07
US63/404352 2022-09-07
US202363480365P 2023-01-18 2023-01-18
US63/480365 2023-01-18
PCT/US2023/064027 WO2023173005A2 (en) 2022-03-09 2023-03-09 Preventive treatment of migraine

Publications (1)

Publication Number Publication Date
CN119421710A true CN119421710A (zh) 2025-02-11

Family

ID=87936018

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380026078.8A Pending CN119421710A (zh) 2022-03-09 2023-03-09 偏头痛的预防治疗

Country Status (8)

Country Link
US (1) US20230321055A1 (https=)
EP (1) EP4489856A4 (https=)
JP (1) JP2025508004A (https=)
CN (1) CN119421710A (https=)
AU (1) AU2023231645A1 (https=)
CA (1) CA3244873A1 (https=)
MX (1) MX2024010878A (https=)
WO (1) WO2023173005A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20210121541A1 (en) * 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
CN116390712A (zh) * 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛

Also Published As

Publication number Publication date
US20230321055A1 (en) 2023-10-12
JP2025508004A (ja) 2025-03-21
CA3244873A1 (en) 2023-09-14
WO2023173005A2 (en) 2023-09-14
MX2024010878A (es) 2024-09-17
WO2023173005A3 (en) 2023-11-23
EP4489856A4 (en) 2026-04-15
AU2023231645A1 (en) 2024-09-12
EP4489856A2 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
CN119421710A (zh) 偏头痛的预防治疗
Schmidt Alvimopan (ADL 8-2698) is a novel peripheral opioid antagonist
Hale et al. Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study
Russell et al. Sodium oxybate reduces pain, fatigue, and sleep disturbance and improves functionality in fibromyalgia: results from a 14-week, randomized, double-blind, placebo-controlled study
Giubilei et al. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments—could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study
Koffler et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome
Rao et al. Clinical trial: effects of botulinum toxin on levator ani syndrome–a double‐blind, placebo‐controlled study
US12090148B2 (en) Treatment of migraine
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
KR20200036919A (ko) 편두통의 치료에 사용하기 위한 라스미디탄 및 cgrp 길항제의 조합 요법
BR112020005998A2 (pt) uso de formulação de fenfluramina na redução em número e em frequências de crises convulsivas em populações de pacientes
Berger et al. Lasmiditan for the treatment of migraines with or without aura in adults
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
Roth et al. The effect of eszopiclone in patients with insomnia and coexisting rheumatoid arthritis: a pilot study
Zanatta et al. Should we use nintedanib as early therapy in patients with SSc-ILD?
KR20170120708A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
Al‐Qassab et al. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study
US20190224186A1 (en) Treatment of multiple sclerosis with chs-131
US20040142968A1 (en) Method and kit for treating lower bowel pain
Simmons et al. Enhancing methods for the delayed onset muscle soreness (DOMS) pain model
Chiche et al. (420) NEO6860, a novel modality selective TRPV1 antagonist: results from a phase I, double-blind, placebo-controlled study in healthy subjects
Dmochowski The puzzle of overactive bladder: controversies, inconsistencies, and insights
RU2828983C1 (ru) Способ лечения хронической мигрени
Scalco et al. Crossover randomized controlled trial of bumetanide to rescue an attack of exercise induced hand weakness in hypokalaemic periodic paralysis
Shih Development of a novel acetaminophen formulations that without hepatotoxic side effect

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination